Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines

  • Jaime Feliu
  • Javier Sastre
  • Joan Maurel
  • Dolores Isla
Clinical Guides in Oncology

DOI: 10.1007/s12094-011-0694-x

Cite this article as:
Feliu, J., Sastre, J., Maurel, J. et al. Clin Transl Oncol (2011) 13: 536. doi:10.1007/s12094-011-0694-x


While hepatocellular carcinoma (HCC) is a relatively common tumour with an annual incidence in the EU of 8 cases/100,000 inhabitants, bile tract carcinoma (BTC) is much less common, with an incidence of 4 cases per 100,000 inhabitants per year. In both cases, when planning treatment it is essential to perform accurate staging, evaluate hepatic functional reserve and performance status, and obtain the opinion of the patient. The only curative treatment is surgery. However, several interventional radiological techniques can help to achieve local disease control and the alleviation of symptoms. In addition, sorafenib (HCC) and chemotherapy (BTC) may contribute to prolong survival in patients with disseminated disease. Therefore, the therapeutic strategy should always be discussed and planned within a multidisciplinary tumour board.


Hepatocellular carcinoma Biliary tract carcinoma Guidelines Multidisciplinary treatment 

Copyright information

© Feseo 2011

Authors and Affiliations

  • Jaime Feliu
    • 1
  • Javier Sastre
    • 2
  • Joan Maurel
    • 3
  • Dolores Isla
    • 4
  1. 1.Medical Oncology DepartmentHospital Universitario La Paz (IdiPAZ), RETICCMadridSpain
  2. 2.Medical Oncology DepartmentHospital Clínico Universitario, RETICCMadridSpain
  3. 3.Medical Oncology DepartmentHospital Clinic de Barcelona, RETICCBarcelonaSpain
  4. 4.Medical Oncology DepartmentHospital Lozano BlesaZaragozaSpain

Personalised recommendations